% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Apr 23, 2014 9:05 AM Flag

    This earnings report could disappoint

    I can't think of any milestones, progress or anything that would trigger any revs. The recent pattern is decent earnings, a PR that sounds really exciting then a debacle on the call when analysts start asking questions and the price falls. Let's hope they do some better prep for the analyst Q&A, but doubtful. I only want to hear one thing, we are considering all options to improve shareholder value including a sale, well maybe a second thing, DJ is planning to retire and we are looking for a successor.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yeah but some of this could already be priced into the stock. We're at 13-14 dollars after falling from 16 to 18. I think that stable and improving sales would be good enough to move us up a tick.

    • Do you think Kadcyla sales could be a surprise? I hear that it is being given as a first line therapy

      • 2 Replies to atomsmith
      • Here's the Q1 sales info from Roche. $102MM in sales for Kadcyla in Q1. Also on April 17 Roche announced the launch of Kadcyla in Japan.

        HER2 franchise (Herceptin, Perjeta, Kadcyla) (+17%) for HER2-positive breast cancer and HER2-
        positive metastatic (advanced) gastric cancer. Herceptin sales rose 3% overall, with 4% growth in the
        United States, 2% in Europe and 23% in Japan. International markets were stable, impacted by some
        phasing of sales in Mexico and political instability in Iraq, however growth remained strong in China
        from patient access programmes; and in Brazil with sales to the public healthcare system. Uptake for
        the subcutaneous formulation of Herceptin has been very positive since its approval in Europe in
        2013 and it is now available in many markets, including Germany and the UK. Demand for recently
        launched medicines Perjeta and Kadcyla was very strong in the first quarter. Perjeta (178 million
        Swiss francs), a medicine which is combined with Herceptin, grew significantly in the United States
        in both metastatic and pre-surgical breast cancer. Uptake in Europe was also very strong, especially
        in Germany and the UK. Kadcyla (102 million Swiss francs) is a targeted cancer medicine that can
        attach to HER2-positive cancer cells and deliver chemotherapy directly to them, resulting in a highly
        potent treatment with fewer adverse side effects. There was good initial uptake in Europe for Kadcyla
        (primarily Germany), as well as continued growth in the United States. Following approvals in Japan
        and the EU in late 2013, reimbursement discussions are well underway in these markets.

      • Roche has probably already reported Kadcyla sales for Q1. IMGN is paid one quarter later, so there's no upside revenue surprise potential for this quarter from Kadcyla.

2.82-0.05(-1.74%)Sep 23 4:00 PMEDT